The London, UK-based contract research organisation offers outsourced services for early phase trials including Adaptive, Thorough-QT, Japanese Bridging Studies and Patient Studies in oncology and indications like amyloidosis.
The new centre in London Bridge offers expanded capacity in the capital, designed to help Richmond conduct further patient recruitment locally through the NHS.
“London [has] 8.3 million NHS patients, a third of which were born overseas, provides an excellent platform for clinical research organisations like Richmond Pharmacology,” said Sarah Haywood, CEO of Med City UK.
Based out of national health service (NHS) teaching hospitals Croydon University Hospital and St George's University of London, Richmond claims that overall it conducts approximately 10% of all Phase I studies performed in the UK, and 1 in every 100 studies worldwide.
To do this, the firm utilises a data management system able to cope with its 200,000 patient database called RPL Data Management, which it launched as a service in 2009.
Jorg Taubel, CEO of Richmond Pharmacology said: “The opening of our new research facility, at what was formerly known as the Guy’s Drug Research Unit, is an exciting addition to our research capability, and will help us to provide the best possible support for our clients in their drive to increase the effectiveness and cost efficiency of developing new drugs and taking them to market.”
Quintiles Ltd. also has Phase I research links at the Drug Research Unit on Guy’s campus.